Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Longitudinal Evaluation of Adding Docetaxel to ADT and Novel Hormone Treatment for Patients With High Volume Metastatic Hormone Sensitive Prostate Cancer in Order to Assess Relative Effectiveness: the Case of "Triple" Versus "Double" Therapy

NCT06446401 is registered in ClinicalTrials.gov with Uppsala University as lead sponsor.

NCT NCT06446401
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06446401 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Longitudinal Evaluation of Adding Docetaxel to ADT and Novel Hormone Treatment for Patients With High Volume Metastatic Hormone Sensitive Prostate Cancer in Order to Assess Relative Effectiveness: the Case of "Triple" Versus "Double" Therapy
Lead sponsor
Uppsala University
Phase
Observational
Overall status
Recruiting
Start date
October 20, 2024
Completion date
December 31, 2031
Enrollment
1,400 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

prostate cancer